Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q3 2017 · 10-Q
Revenue$12.53M$12.53M+24.6% vs Q3 2016 Net Income-$4.07M-$4.07MN/M vs Q3 2016 EPS Diluted-$0.31-$0.31N/M vs Q3 2016 Gross Profit$2,563,438+51.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Operating Cash Flowderived-$98,582N/M Margins · derivedGross margin20.5%+3.6 pt vs Q3 2016
Operating margin-31.5%−18.6 pt vs Q3 2016
Net margin-32.5%−15.4 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 13, 2017 · 44 d after period end